Rizatriptan Tablet Versus Wafer: Patient Preference
Authors:
- 1 May 2000
- journal article
- research article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 40 (5) , 371-372
Abstract
After taking both conventional oral rizatriptan tablets and oral disintegrating rizatriptan tablets in the treatment of migraine with or without aura, patients were permitted to select their formulation preference. All adult patients who had requested continuation of rizatriptan during a 6‐month period were included in the study. Of the 367 patients studied, 188 selected the oral disintegrating tablet, while 179 preferred the conventional tablet. Although individual patients had strong preferences for one preparation over the other, no group preference was found.Keywords
This publication has 5 references indexed in Scilit:
- Efficacy and Safety of Rizatriptan Wafer for the Acute Treatment of MigraineCephalalgia, 1999
- Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 1998
- Crossover Comparison of Rizatriptan 5 mg and 10 mg Versus Sumatriptan 25 mg and 50 mg in MigraineHeadache: The Journal of Head and Face Pain, 1998
- A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacksNeurology, 1998
- Rizatriptan (MAXALT) for the Acute Treatment of Migraine and Migraine Recurrence. A Placebo‐Controlled, Outpatient StudyHeadache: The Journal of Head and Face Pain, 1998